Breaking News
FONT-SIZE Plus   Neg
Share SHARE

WuXi PharmaTech Q4 Profit Edges Up, Sees 2013 Earnings Above View

RELATED NEWS
Trade WX now with 

China-based drug-research contractor WuXi PharmaTech (Cayman) Inc. (WX: Quote) on Thursday reported a 1 percent increase in profit for the fourth quarter as double-digit revenue growth was offset by higher expenses.

Looking ahead, the company forecasts earnings for the first quarter and fiscal 2013 to be mostly higher than analysts' estimates. The company's shares gained 4 percent in extended trade.

The company noted that lower gains on foreign-exchange forward contracts of $3 million and a 15 percent increase in income tax expense offset higher revenue in the fourth quarter.

Selling and marketing expenses for the fourth quarter surged 56 percent to $4.73 million, while general and administrative expenses increased 5 percent to $17.95 million and research and development expenses increased 13 percent to $2.50 million. The latest quarter's results also include impairment charges for goodwill and intangible assets of $3.42 million.

Laboratory Services net revenues for the quarter increased 19 percent from the year-ago period to $103.77 million, driven by the company's comprehensive and integrated discovery and development services. China-based laboratory services revenues rose 22 percent and U.S.-based laboratory services net revenues increased 7 percent.

Manufacturing Services net revenues grew 4 percent from last year to $21.89 million, reflecting increased demand for clinical-trial materials in the company's research manufacturing business. This more than offset lower demand for advanced intermediates in the company's commercial manufacturing business.

Gross margin declined to 38.8 percent from 39.2 percent in the prior-year period.

WuXi's fourth-quarter net income was $23.82 million or $0.33 per American Depositary Share or ADS, slightly up from $23.48 million or $0.31 per ADS in the previous-year quarter.

Excluding items, adjusted net income for the quarter was $27.51 million or $0.38 per ADS, compared to $26.94 million or $0.36 per ADS in the same period last year. On average, six analysts polled by Thomson Reuters expected the company to report earnings of $0.30 per share for the quarter. Analysts' estimates typically exclude special items.

Net revenues for the quarter grew 16 percent to $125.66 million from $108.54 million in the prior-year period. Analysts had a consensus revenue estimate of $123.71 million.

For fiscal 2012, WuXi's net earnings increased to $86.58 million or $1.19 per ADS from $80.98 million or $1.07 per ADS last year. Adjusted net income was $102.17 million or $1.40 per ADS, compared to $93.41 million or $1.24 per ADS in the prior year.

Net revenues for the year grew 23 percent to $499.91 million from $407.18 million in the previous year.

Analysts expected the company to earn $1.32 per share for the year on revenues of $497.64 million.

Looking ahead to the first quarter, WuXi forecasts earnings of $0.26 to $0.27 per ADS, adjusted earnings of $0.31 to $0.32 per ADS and revenues in a range of $129 million to $131 million. Street expects the company to earn $0.31 per share for the quarter on revenues of $131.8 million.

For fiscal 2013, WuXi forecasts earnings of $1.26 to $1.30 per ADS, adjusted earnings of $1.49 to $1.53 per ADS, and revenues of $565 million to $575 million. Analysts expect earnings of $1.44 per share for the year on revenues of $571.58 million.

WuXi's board of directors has approved a share repurchase plan that has authorized the company to repurchase up to $100 million of its American depositary shares over the next 18-24 months.

WX closed Thursday's regular trading at $17.30, up $0.08 or 0.46 percent on a volume of 149,045 shares. In after-hours, the stock further gained $0.71 or 4.10 percent to $18.01.

Register
To receive FREE breaking news email alerts for WuXi PharmaTech (Cayman) Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Beverages giant Coca-Cola Co. reported Tuesday a profit for the third quarter that decreased 14 percent from last year, despite higher worldwide volumes, reflecting a revenue drop. Adjusted earnings per share matched analysts' expectations, even as quarterly revenues missed their estimates. Following the announcement, the company's shares are trading more than five percent lower in early deals. Apple Inc. said Monday that its fourth quarter profit rose 13% from last year, driven by strong sales of its iPhones and Mac computers. The company's quarterly earnings per share also came in above analysts' expectations as did its quarterly sales. At the same time, the company gave an upbeat revenue forecast for the current quarter, which includes the all important holiday season. Programmable chipmaker Xilinx Inc. (XLNX) said Thursday after the markets closed that its second quarter profit rose 21% from last year, helped by higher revenue and better cost control. The company's quarterly earnings per share also came in above analysts' expectations as did its quarterly revenue....
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.